NCT03446053View on ClinicalTrials.gov

A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

February 7, 2019

Study Completion Date

February 7, 2019

Conditions
Healthy VolunteersAnti-Bacterial AgentsMethicillin-Resistant Staphylococcus AureusMethicillin-Sensitive Staphylococcus Aureus Infection
Interventions
BIOLOGICAL

N-Rephasin® SAL200

continuous intravenous infusion over 60 minutes

OTHER

INT200-Placebo

Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Intron Biotechnology, Inc.

INDUSTRY